Healthcare veterans from biopharma industry, agency and advisory firms will deliver tech-enabled insight, influence and action NEW YORK–(BUSINESS WIRE)–Real ChemistryHealthcare veterans from biopharma industry, agency and advisory firms will deliver tech-enabled insight, influence and action NEW YORK–(BUSINESS WIRE)–Real Chemistry

Real Chemistry Establishes RC Resolve, an Advisory Practice for Healthcare’s Most Critical Business, Regulatory and Value Inflection Points

2026/01/09 21:15
6분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 crypto.news@mexc.com으로 연락주시기 바랍니다

Healthcare veterans from biopharma industry, agency and advisory firms will deliver tech-enabled insight, influence and action

NEW YORK–(BUSINESS WIRE)–Real Chemistry today announced the launch of RC Resolve, a healthcare advisory practice designed to help leaders navigate the value inflection points where science, business, economics, policy and risk management intersect. RC Resolve offers a new end-to-end model of healthcare advisory informed by deep expertise and real-time insights to deliver communication strategies and execution that drive desired outcomes.

“The healthcare industry is at a critical juncture, with the pace, complexity and consequences of decision-making accelerating rapidly,” said Jennifer Gottlieb, Global President and Head of Integrated Communications at Real Chemistry. “Healthcare leaders today are seeking highly specialized partners that combine deep industry expertise with advisory capabilities to navigate the regulatory shifts, reputational risk and financial uncertainties of the operating environment that make advancing business and science more complicated, more risky and potentially more costly. RC Resolve was created to meet this need, building on Real Chemistry’s 25-year legacy as a leading data-driven healthcare partner – bringing together seasoned industry leaders who have walked in our clients’ shoes and have decades of experience to help organizations move forward with clarity, confidence and decisive action.”

RC Resolve leverages proprietary, AI-powered intelligence, including ReputAI, an advanced reputation measurement and predictive message-testing suite, and HealthGEO, which assesses how large language models influence corporate perception to drive message clarity and measurable impact. Backed by Real Chemistry’s 2,000+ experts across life sciences, marketing communications and technology, RC Resolve provides healthcare advisory counsel – combining deep sector perspective with strategic foresight – to help organizations navigate complexity, strengthen trust and stay ahead of change.

RC Resolve’s advisory practice spans critical areas that meet clients’ most pressing communication needs, including:

  • Policy, Public Affairs and Access
  • Issues, Crisis and Risk Management
  • Transformation and Change Management
  • Executive Communications
  • Corporate Strategy and Reputation
  • Financial and Transaction Communications

RC Resolve’s Seasoned Senior A-Team

“RC Resolve was built specifically to bring together senior health advisors who understand the pressures from the outside in and can help leaders make confident, enterprise-level decisions with speed and precision – when it matters most,” said Sherry Pudloski, Group President of RC Resolve and Corporate Affairs at Real Chemistry. Pudloski previously served as chief communications and corporate affairs officer at Seagen, Zoetis and Guardian Life and held senior communications and strategy roles at Pfizer and Novartis.

RC Resolve comprises veterans with more than 20 years of experience advising leaders in the boardroom, newsroom, crisis room and policy environment, including:

  • Bridget Walsh, Head of Policy, Public Affairs and Access, held government affairs and policy leadership roles at Pfizer and Boehringer Ingelheim, including 10 years on Capitol Hill as a senior staffer to U.S. Senators.
  • Margaret (Maggie) Farley, Head of Issues, Crisis and Risk Management, is a renowned counselor across biopharmaceutical and medical device communications who led health crises and issues management at Edelman for two decades.
  • Amy Atwood, Head of Transformation and Change Management, brings deep experience leading corporate communications, change management and strategic transformation across global healthcare enterprises, most recently as Vice President, U.S. and Global Corporate Communications at Takeda.
  • Shoreen Maghame, Head of Executive Communications, is a strategic communications advisor to C-suite executives on global launches, crises and reputation management whose early career experience as an on-air journalist informs her practical, media-savvy approach to executive communications.
  • Piper Evans, Head of Corporate Strategy and Reputation, advises executives across academic medicine, integrated delivery systems, emerging biotechs and global health organizations. She joins from FGS Global and previously held positions at McKinsey & Company, Purple Strategies and the Public Affairs Council.
  • Leslie Isenegger, Head of Client Development, has industry-leading policy and pricing expertise and was most recently head of Real Chemistry’s Corporate Pricing and Public Affairs practice. She previously held positions at the Centers for Medicare & Medicaid Services (CMS) and the Greater New York Hospital Association.

RC Resolve’s Healthcare Advisory Council

Backing up the RC Resolve A-Team is a Healthcare Advisory Council of senior leaders with deep experience across regulatory, legal, health economics, healthcare financing and corporate affairs who will provide enterprise-level perspective and strategic decision-making.

Current members include Jim Weiss, Founder and Chairman of Real Chemistry; Shankar Narayanan, Chief Executive Officer (CEO) at Real Chemistry and former Partner, McKinsey & Company; Kirsten Axelsen, health economics expert and Senior Policy Advisor at DLA Piper; Murphy Gallagher, Senior Managing Director at Leerink Partners; Erica Jefferson, former Associate Commissioner for External Affairs at the U.S. Food and Drug Administration (FDA); and Alan Minsk, Partner and Co-Chair of the Food and Drug Practice team at Arnall Golden Gregory LLP. The membership of RC Resolve’s Healthcare Advisory Council will evolve alongside the healthcare and policy landscape, ensuring access to relevant expertise as novel issues and opportunities emerge.

“As a privately held company focused exclusively on healthcare, we’ve stayed true to our commitment to invest where it matters most for our clients’ growth,” said Narayanan. “Building on our strong momentum in 2025 – including expansion of our omni-first precision marketing and media group – RC Resolve is one of several new offerings we’re bringing to market in 2026, along with continued advances in AI-driven intelligence and delivery and our expanding global footprint.”

About RC Resolve

RC Resolve is Real Chemistry’s advisory practice for healthcare’s most critical business, regulatory and value inflection points where science, business, economics, policy and risk management intersect. RC Resolve combines insight, influence and decisive action to help organizations achieve desired outcomes and emerge stronger, more trusted and better prepared for what’s next.

About Real Chemistry: 25 Years of Future-Focused Healthcare

Celebrating its 25th anniversary this year, Real Chemistry is a tier-one partner to the world’s most innovative life sciences and healthcare companies. As a leading provider of AI-powered audience analytics and insights, Real Chemistry helps the healthcare industry better understand, reach and engage critical audiences to improve the healthcare experience for all. Anchored by our culture of innovation and creativity, Real Chemistry’s 2,000+ global experts across life sciences, marketing communications and technology are singularly focused on navigating the complexities of bringing scientific advances to market and, most importantly, to the people who need them. Learn more at www.realchemistry.com.

Contacts

Media Contact:

media@realchemistry.com

시장 기회
RealLink 로고
RealLink 가격(REAL)
$0.06729
$0.06729$0.06729
+2.06%
USD
RealLink (REAL) 실시간 가격 차트
면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, crypto.news@mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

USD1 Genesis: 0 Fees + 12% APR

USD1 Genesis: 0 Fees + 12% APRUSD1 Genesis: 0 Fees + 12% APR

New users: stake for up to 600% APR. Limited time!